COVID-19疾病严重性的决定因素 - - 从包括癌症在内的初级和二级免疫疾病中吸取教训
Antonio G Solimando1, Max Bittrich2, Endrit Shahini3
1Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), Aldo Moro Bari University, 70100 Bari, Italy.
包括癌症在内的免疫疾病患者表现出不同的COVID-19脆弱性. 虽然一些癌症患者的疫苗反应较低,但许多患者具有严重的COVID-19疾病的一般风险因素.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 在COVID-19大流行初期,免疫功能受损的个体,包括癌症患者,被认为具有严重疾病和死亡的高风险.
- 新出现的证据显示,在患有初级和二级免疫疾病的患者中,COVID-19的脆弱性存在显著的异质性.
研究的目的:
- 审查当前关于免疫障碍如何影响COVID-19严重程度和疫苗反应的知识.
- 在COVID-19的背景下,检查癌症作为二级免疫障碍.
主要方法:
- 文献综述综合现有科学证据.
- 对免疫力低下和癌症人群中COVID-19结果和疫苗接种的研究分析.
主要成果:
- 血液性恶性瘤患者有时会在接种疫苗后的血清转化率降低.
- 许多癌症患者的严重COVID-19风险因素是固有的 (例如,进展性疾病) 或与一般人群相似 (年龄,男性性别,并发症).
结论:
- 需要进一步的研究,以确定患有严重COVID-19风险较高的特定患者亚组.
- 免疫疾病可以作为理解SARS-CoV-2免疫反应的模型.
- 长度血清学研究对于确定不同人群免疫持续时间至关重要.
更多相关视频
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
相关概念视频
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Psychoneuroimmunology: Diabetes and Cancer
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
